[Federal Register Volume 87, Number 157 (Tuesday, August 16, 2022)]
[Notices]
[Pages 50340-50341]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-17613]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Advisory 
Council on Drug Abuse.
    The meeting will be held as a virtual meeting and is open to the 
public, as indicated below. Individuals who plan to view the virtual 
meeting and need special assistance or other reasonable accommodations 
to view the meeting, should notify the Contact Person listed

[[Page 50341]]

below in advance of the meeting. The open session will be videocast and 
can be accessed from the NIH Videocasting and Podcasting website 
(http://videocast.nih.gov/).
    A portion of this meeting will be closed to the public in 
accordance with the provisions set forth in sections 552b(c)(4) and 
552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.

    Name of Committee: National Advisory Council on Drug Abuse.
    Date: September 13, 2022.
    Closed: 11:00 a.m. to 12:15 p.m.
    Agenda: To review and evaluate grant applications.
    Open: 12:45 p.m. to 5:00 p.m.
    Agenda: Presentations and other business of the Council.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of 
Extramural Research, Office of the Director, National Institute on 
Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown 
Street, Bethesda, MD 20852, 301-443-6480, [email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to Gillian Acca at 
[email protected]. The statement should include the name, 
address, telephone number and when applicable, the business or 
professional affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and 
any additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: August 11, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-17613 Filed 8-15-22; 8:45 am]
BILLING CODE 4140-01-P